Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Vaxcyte, retaining the price target of $50.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tara Bancroft’s rating is based on promising data from Vaxcyte’s vaccine trials, which suggest strong potential for their products. The recent Phase II data for VAX-24 in infants showed that non-inferiority criteria for immunogenicity were met for most serotypes, indicating robust immune responses. The dose-dependent increase in immunogenicity without evidence of increased carrier suppression further supports the efficacy of the vaccine, particularly with the optimized dosing strategy being tested in the VAX-31 infant study.
Additionally, the potential for improved titers when VAX-24 is co-administered with a flu vaccine provides an added advantage over existing vaccines like Prevnar. The expectation of positive Phase III data in 2026 and the current undervaluation of Vaxcyte’s stock contribute to the Buy rating. These factors combined suggest a strong outlook for Vaxcyte, making it an attractive investment opportunity.